FDA Medical Device Labeling and IFU Requirements: What You Must Get Right

The word "label" in everyday language refers to the physical label affixed to a product or its package. FDA's use of "labeling" is considerably broader.

Under Section 201(m) of the FD&C Act, labeling means "all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article."

The phrase "accompanying such article" has been interpreted broadly by courts and FDA to include materials that are not physically attached to the device but that relate to it. This includes Instructions for Use (IFUs) and quick reference guides, packaging inserts, promotional brochures distributed alongside the device, website content used to promote and explain a device's use, sales training materials (if they are considered to accompany the device in commerce), and videos or electronic materials distributed with or for the device.

This broad definition has practical consequences. A claim that appears in a promotional brochure but not in cleared labeling may constitute promotion of an off-label use. A website page that describes clinical uses not covered by cleared labeling is labeling and must stay within the bounds of the cleared intended use.

The Legal Distinction Between a Label and Labeling

A "label" is the physical item under 21 CFR 801.1: the display of written, printed, or graphic matter on the immediate container of an article. The "immediate container" is the container the device sits in when you pick it up.

"Labeling" is the broader category. Every label is labeling, but not all labeling is a label. Why does the distinction matter? Because Part 801 places certain required information on the label specifically, meaning it must appear on the physical container or wrapper of the device. You cannot satisfy that requirement by putting the information only in an IFU. Other information appropriately belongs in an IFU. Understanding which category each required element falls into is fundamental to labeling compliance.

Required Elements Under 21 CFR Part 801

Name and place of business (21 CFR 801.1)

Every device label must identify the manufacturer, packer, or distributor by name and place of business. For a device sold under a private label arrangement, the label must identify the entity responsible for the device and its address.

Directions for use (21 CFR 801.5)

Every device must bear "adequate directions for use," meaning directions under which a layperson or the intended user can use the device safely and for the purposes for which it is intended. 21 CFR 801.5 sets the standard; 21 CFR 801.109 creates the exemption mechanism (discussed below).

Statement of identity (21 CFR 801.61)

The label must bear the established (common or usual) name of the device as a statement of identity under 21 CFR 801.61. Where a proprietary (trade) name is also used, the established name should appear in conjunction with it.

Net quantity (21 CFR 801.62)

For devices sold by count, weight, or measure, the label must bear a declaration of net quantity of contents under 21 CFR 801.62.

Prescription device labeling (21 CFR 801.109)

Prescription devices are exempt from the "adequate directions for use" requirement for lay users because the device is sold on the prescription of a licensed practitioner. Instead, the label must include directions for the prescribing practitioner and warnings adequate to protect user safety. Professional labeling for prescription devices follows a different structure than OTC device labeling.

Instructions for Use (IFU): What Must Be Included

An IFU is the primary mechanism for communicating device-specific operational information to the intended user. The IFU supplements the label; it does not replace it. Information required on the label by 21 CFR Part 801 cannot be relocated to the IFU.

FDA expects an IFU to include, as applicable:

Indications for use. The specific disease, condition, or patient population for which the device is intended. This must align precisely with the intended use stated in the 510(k), De Novo, or PMA clearance or approval. Any description of use that goes beyond the cleared indication is off-label promotion.

Contraindications. Conditions or patient characteristics under which the device should not be used because the risk exceeds the benefit. Contraindications discovered in clinical studies or post-market experience must be included.

Warnings. Information about risks that could result in death or serious injury if the device is used incorrectly. Warnings describe hazards that the user must be aware of before use.

Precautions. Conditions under which special care must be taken to ensure safe use, but where the risk is less severe than what would constitute a warning.

Step-by-step directions. The sequence of actions the user takes to set up, operate, maintain, and, where applicable, dispose of the device. These must be written for the intended user: a consumer-use device requires directions a layperson can follow; a surgical device may assume clinical training. In practice, whether directions are adequate for the intended user is established through human factors and usability engineering, which evaluates use-related risk and confirms that the intended user can perform critical tasks safely. Use-related findings from that work commonly drive the wording and structure of the IFU. See the companion article on human factors engineering for medical devices.

Technical specifications. Performance parameters, compatible accessories, storage and handling conditions, and device limitations.

Symbol definitions. If the label or IFU uses graphical symbols, the IFU (or a separate symbol legend) must define each symbol. FDA expects symbols to conform to recognized standards, primarily ISO 15223-1:2021, the current FDA-recognized edition, together with FDA's use-of-symbols labeling provision at 21 CFR 801.15(c).

Manufacturer information. Name, address, and contact information for the manufacturer and, where applicable, the authorized representative.

UDI: The Unique Device Identifier Requirement

The UDI rule, implemented in phases following the FDA Safety and Innovation Act of 2012, requires that the label and package of every medical device bear a Unique Device Identifier. The UDI system requirements are set out in 21 CFR Part 830, while the requirement for a device label to bear a UDI is codified in 21 CFR Part 801 (beginning at 21 CFR 801.20, with related provisions at 801.30 through 801.57).

What the UDI consists of

The UDI has two parts:

• Device Identifier (DI): A mandatory, fixed portion that identifies the device version or model. The DI is associated with the listing information in FDA's Global Unique Device Identification Database (GUDID).
• Production Identifier (PI): A conditional, variable portion that identifies one or more of: lot or batch number, serial number, manufacturing date, and expiration date, depending on what information is applicable to the device.

Format requirements

The UDI must appear on the label in two formats:

1. Human-readable interpretation (HRI): The UDI written in plain text that a person can read.
2. Automatic Identification and Data Capture (AIDC): A machine-readable barcode. FDA accepts barcodes conforming to either the GS1 or HIBCC standards, both of which are FDA-accredited issuing agencies.

Which devices require a UDI

Most Class II and Class III medical devices must carry a UDI on the label. Many Class I devices are also subject to UDI requirements. The compliance dates for UDI phased in by device class, with Class III devices first, followed by Class II, then Class I. Class I and unclassified devices became subject to UDI labeling and direct-marking requirements on September 24, 2022, with FDA exercising enforcement discretion for standard date formatting and GUDID data submission for those devices until December 8, 2022. Devices implanted in the human body are also required to bear a UDI on the device itself, not just the label.

GUDID submission

Manufacturers must submit device information to FDA's GUDID within specific timelines. The GUDID is a publicly accessible database that receives the DI and associated device information for each labeled device. Failure to submit required GUDID information is a labeling violation.

Common Labeling Pitfalls That Trigger Enforcement Action

FDA Warning Letters for labeling violations follow recognizable patterns. The most common issues include:

Off-label claims in promotional materials. A promotional brochure, website page, or sales training material that describes uses not covered by the cleared or approved labeling constitutes a misbranded device. FDA does not require a separate enforcement action to establish this: if the material accompanies the device or is used in its promotion, it is labeling, and its claims must stay within the cleared intended use.

Promotional claims embedded in the IFU. An IFU that describes outcomes, clinical benefits, or performance characteristics in language more consistent with promotional copy than neutral directions for use creates misbranding risk. The IFU is a technical document, not a marketing document.

Moving required label elements to the IFU. Certain information required on the label by Part 801 cannot be relocated to the IFU. If required name-and-place-of-business information, required directions for use, or UDI information are not on the label itself, the device is misbranded.

Non-compliant symbol use. Using a symbol on a label without defining it in the IFU or using a symbol that does not conform to a recognized standard creates a labeling deficiency. FDA expects symbols to be from recognized standards and to be defined in writing accessible to the device user.

Labeling changes after clearance without evaluation. Changes to labeling after initial clearance must be evaluated to determine whether they require a new premarket submission. Some labeling changes trigger a 510(k) requirement; others do not. Failing to conduct this evaluation and simply updating the label without FDA interaction is a compliance gap that surfaces during inspections.

Inadequate directions for use. Directions that assume a higher level of user knowledge than the cleared intended user population possesses, that omit critical steps, or that are organized in a way that creates use error risk, can result in labeling deficiencies and, more importantly, adverse events traceable to inadequate labeling.

Labeling as a Design Output Under the QMSR

Under the FDA Quality Management System Regulation (QMSR, effective February 2, 2026), labeling is a design output subject to design controls under ISO 13485:2016 Clause 7.3. This means labeling must go through a defined design and development process with documented inputs, review, verification, and approval; changes to labeling must flow through a change control process; and the labeling in its released form must be traceable to the device master record.

Marketing teams that develop labeling content outside the quality system, or that treat promotional materials as exempt from design control review, create a compliance vulnerability. Every piece of material that will accompany the device or be used in its promotion should have a defined path through the quality system, including marketing team-created materials.

For an overview of what the QMSR changed from the legacy QSR, see QMSR Explained: What the FDA Quality System Regulation Change Means for Device Makers.

How Labeling Boundaries Define Marketing Strategy

The cleared intended use statement in a 510(k), De Novo, or PMA is not just a regulatory artifact. It is the boundary within which every marketing activity must operate. Claims in advertising, promotional emails, conference presentations, website copy, and sales conversations must all stay within that boundary.

Buzzbox Media works with device companies to build marketing programs that are commercially effective within the cleared labeling framework. Understanding what the cleared labeling says is the starting point for every campaign, content piece, and piece of sales collateral. See our medical device marketing services for more on how we connect regulatory strategy to commercial messaging.